Later, in 2018, based on the IMpower150 trial (NCT02366143), atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin was approved for the first‐line treatment of advanced nonsquamous NSCLC without EGFR or ALK mutation.345. This evidence concerns the gene ALK and non-small cell lung carcinoma.